Innate Pharma (IPHYF) Other Non-Current Liabilities (2017 - 2025)

Innate Pharma's Other Non-Current Liabilities history spans 9 years, with the latest figure at $386462.5 for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 31.99% year-over-year to $386462.5; the TTM value through Dec 2025 reached $386462.5, up 31.99%, while the annual FY2025 figure was $386462.5, 30.31% up from the prior year.
  • Other Non-Current Liabilities reached $386462.5 in Q4 2025 per IPHYF's latest filing, up from $292795.1 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $648791.8 in Q4 2023 to a low of $202009.0 in Q4 2022.
  • Average Other Non-Current Liabilities over 5 years is $363896.6, with a median of $292795.1 recorded in 2024.
  • Peak YoY movement for Other Non-Current Liabilities: skyrocketed 221.17% in 2023, then plummeted 54.87% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $289424.7 in 2021, then crashed by 30.2% to $202009.0 in 2022, then surged by 221.17% to $648791.8 in 2023, then tumbled by 54.87% to $292795.1 in 2024, then surged by 31.99% to $386462.5 in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Other Non-Current Liabilities are $386462.5 (Q4 2025), $292795.1 (Q4 2024), and $648791.8 (Q4 2023).